Psoriasis | Unmet Need | US/EU | 2018
IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17 inhibitors are starting to be prescribed in earlier lines of therapy, the biologics market is still dominated by TNF-α inhibitors and Stelara. Nonetheless, emerging therapies may find opportunities to address the unmet needs in the moderate to severe psoriasis market identified in this report.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for psoriasis?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?
- What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new moderate to severe psoriasis drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European dermatologists fielded in January and February 2018.
Key companies: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis.
Key drugs: Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz, Tremfya.
